HomeCompareBKEAF vs PFE

BKEAF vs PFE: Dividend Comparison 2026

BKEAF yields 4.69% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BKEAF wins by $4288.82M in total portfolio value
10 years
BKEAF
BKEAF
● Live price
4.69%
Share price
$1.67
Annual div
$0.08
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4288.87M
Annual income
$4,120,054,081.93
Full BKEAF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — BKEAF vs PFE

📍 BKEAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBKEAFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BKEAF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BKEAF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BKEAF
Annual income on $10K today (after 15% tax)
$398.52/yr
After 10yr DRIP, annual income (after tax)
$3,502,045,969.64/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, BKEAF beats the other by $3,502,023,649.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BKEAF + PFE for your $10,000?

BKEAF: 50%PFE: 50%
100% PFE50/50100% BKEAF
Portfolio after 10yr
$2144.46M
Annual income
$2,060,040,170.32/yr
Blended yield
96.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BKEAF
No analyst data
Altman Z
0.2
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BKEAF buys
0
PFE buys
0
No recent congressional trades found for BKEAF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBKEAFPFE
Forward yield4.69%6.13%
Annual dividend / share$0.08$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$4288.87M$49.6K
Annual income after 10y$4,120,054,081.93$26,258.71
Total dividends collected$4276.97M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BKEAF vs PFE ($10,000, DRIP)

YearBKEAF PortfolioBKEAF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,638$937.69$9,153$693.39+$2.5KBKEAF
2$14,492$2,039.74$8,593$849.25+$5.9KBKEAF
3$20,254$4,747.70$8,336$1,066.78+$11.9KBKEAF
4$34,075$12,402.66$8,437$1,384.80+$25.6KBKEAF
5$75,461$39,001.14$9,013$1,875.40+$66.4KBKEAF
6$242,185$161,441.27$10,306$2,680.72+$231.9KBKEAF
7$1,227,604$968,466.31$12,820$4,101.38+$1.21MBKEAF
8$10,489,305$9,175,769.32$17,673$6,826.70+$10.47MBKEAF
9$157,770,651$146,547,094.08$27,543$12,591.86+$157.74MBKEAF
10$4,288,868,678$4,120,054,081.93$49,560$26,258.71+$4288.82MBKEAF

BKEAF vs PFE: Complete Analysis 2026

BKEAFStock

The Bank of East Asia, Limited, together with its subsidiaries, provides various banking and related financial services. Its personal banking services include corporate, individual, savings, current, time deposit, and supreme accounts; and fixed and call deposits, foreign currency deposits, MAS services, and auto-payroll products, as well as safe deposit boxes and remittance services. The company also provides corporate banking services, such as SME loans and financing guarantee schemes; corporate and commercial financing products, including syndicated and construction loans, acquisition and structured financing, working capital financing, share financing and IPO-related loans, and commercial mortgages; trade finance services and expert trade solutions; factoring services; import and export trade finance; guarantee services; eTradeConnect that allows buyers and sellers to connect, transact, share information, and submit applications for financing through a single platform; cash management services; corporate wealth management products; foreign exchange and treasury products; trade settlement and financing services; onshore and offshore loans; and marine cargo, property, trade credit, employee compensation, pet, medical, life, savings, and endowment insurance plans. In addition, it offers private banking services comprising investment advisory services; investment solutions, such as unit trusts, linked deposits, currency trading and management, global equities and bonds investments, structured products, and options and derivatives; portfolio management services; securities and futures broking services; cyber banking, credit cards, and ATM; and various international services. The company operates 150 outlets in Hong Kong, rest of Greater China, Southeast Asia, the United Kingdom, and the United States. The Bank of East Asia, Limited was incorporated in 1918 and is headquartered in Central, Hong Kong.

Full BKEAF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BKEAF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BKEAF vs SCHDBKEAF vs JEPIBKEAF vs OBKEAF vs KOBKEAF vs MAINBKEAF vs JNJBKEAF vs MRKBKEAF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.